Amanote Research
Register
Sign In
P030 Prognostic Factors for Advanced Lung Adenocarcinoma Patients Who Received Tyrosine Kinase Inhibitor and Radiotherapy
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.10.054
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
December 1, 2018
Authors
H. Yang
B. Chen
Y. Wang
Y. Gong
Y. Xu
L. Zhou
Y. Liu
Y. Lu
Publisher
Elsevier BV
Related search
P11 Tyrosine Kinase Inhibitor Use in Pulmonary Adenocarcinoma
Thorax
Pulmonary
Respiratory Medicine
Volume-Based Growth Tumor Kinetics as a Prognostic Biomarker for Patients With EGFR Mutant Lung Adenocarcinoma Undergoing EGFR Tyrosine Kinase Inhibitor Therapy: A Case Control Study
Cancer Imaging
Nuclear Medicine
Radiology
Ultrasound Technology
Oncology
Radiological
Imaging
Medicine
Survival and Prognostic Factors for Patients With Advanced Hepatocellular Carcinoma After Stereotactic Ablative Radiotherapy
PLoS ONE
Multidisciplinary
Auditory Outcomes in Patients Who Received Proton Radiotherapy for Craniopharyngioma
American Journal of Audiology
Speech
Hearing
Different Mutational Characteristics of the Subsets of EGFR-tyrosine Kinase Inhibitor Sensitizing Mutation-Positive Lung Adenocarcinoma
BMC Cancer
Cancer Research
Oncology
Genetics
Research of Prognostic Role of MSI in Endometrioid Adenocarcinoma Cases That Received Postoperative Radiotherapy
International Journal of Cancer and Clinical Research
Expression and Prognostic Significance of Cyclin‑dependent Kinase Inhibitor 1A in Patients With Resected Gastric Adenocarcinoma
Oncology Letters
Cancer Research
Oncology
Prognostic and Therapeutic Potential of Adenylate Kinase 2 in Lung Adenocarcinoma
Scientific Reports
Multidisciplinary
Fer Protein-Tyrosine Kinase Promotes Lung Adenocarcinoma Cell Invasion and Tumor Metastasis
Molecular Cancer Research
Cancer Research
Oncology
Molecular Biology
